Capital Markets Union: delivering new opportunities for SMEs through venture capital
Date
Address
Event Type
Section
Event Location
Event Description
ACCA, Barclays & UEAPME invite you to
Capital Markets Union : delivering new opportunities for SMEs through venture capital
13 July 2016
15.00h-17.00h, followed by a cocktail reception
Press Club, 95 rue Froissart, Brussels
Small and medium-sized enterprises (SMEs) represent over 99% of businesses in the EU. They play a critical role in global economic development and are the backbone of the EU economy. It is therefore crucial to support them throughout their life cycle– from seed capital during start up, through to investment during their different states of development, to give them the possibility to grow and innovate.
But – as is increasingly well understood – the limits of the traditional debt financing model for SMEs have been exposed by the financial crisis. Broadly speaking, Europe has been over-reliant on bank financing along and its recovery has been held back as a result.
Complementary sources of financing do of course already exist, there are well established alternative listing venues, crowd-funding or peer to peer lending networks, and a range of other new and emerging options. Changing a long standing culture of sole reliance on bank lending is not a simple process however, it takes time and considerable effort to promote and develop the range of complementary options necessary.
Delivering on its Capital Markets Union commitments is a key priority area for the European Commission in 2016. As part of that programme, it has committed to coming forward with a package of measures to stimulate venture capital in the EU ‘before the summer’.
ACCA, Barclays & UEAPME are delighted to invite you to a roundtable discussion to discuss how to create the right environment for the provision of private capital to SMEs and what role it can play in moving us towards our Capital Markets Union.
Please reply to Cécile Bonino, ACCA’s Head of EU Affairs by 30 June to cecile.bonino@accaglobal.com
Draft agenda
14.45-15.00h Registrations
15.00h Welcome remarks, Rebecca McNeil, Head of SME lending, Barclays
15.05h Presentation from Sven Gentner, Head of unit for asset management, DG FISMA, European Commission
15.20h Roundtable moderated by Rosana Mirkovic, Head of Small Business Affairs, ACCA
- Irmfried Schwiman, Deputy Director General, DG GROW
- Dörte Hoppner – Chief Executive Invest Europe
- Alexander von Preysing, Head of Sales, Deutsche Börse Venture Network, Pre-IPO & Capital Markets
- Candace Johnson, President of the EBAN
- Gerhard Huemer, Director, Economy Policy UEAPME
16.20h Q&As
16.40h Key note concluding remarks, Othmar Karas, MEP
16.55h Conclusions, Rebecca McNeil, head of SME lending, Barclays
17.00h Cocktail reception
Related Events
Securing Europe‘s Raw Material Supply in the Context of Resource Efficiency and EU Industry Policy
There is no energy- and resource efficiency, no climate protection, no future technologies for our modern
world without the use of non-ferrous metals.
Monday 5 November 2012 (day 1)
15:00-16:30: European Parliament Briefing (optional): Enterprise Forum members will have the opportunity to attend a briefing on how the European Parliament works. Paul-Henri Spaak Building, Rue Wiertz, B-1047 Brussels
SMEs are the backbone of the European economy. Of the approximately 20 million SMEs in Europe, one third is active in the field of commerce.
COST will be a partner of the fourth European Innovation Summit to be held at the European Parliament in Brussels under the motto 'Building bridges – Creating Synergies'.
Knowledge4Innovation will be organising the 4th European Innovation Summit from 9 to 10 October 2012 in the European Parliament in Brussels.
An existing literature agrees that drug innovation has a significant average effect on extending longevity and improving quality of life. Recognizing the life-saving benefits from the development of new drugs, one of the key decisions faced by the authorities is how to bolster pharmaceutical innovation, and how to bear in mind the potential effects on drug innovation of policies that affect market size, such as policies towards intellectual property rights, procurement mechanisms and competition policy.
Pages
Events of the week
Jobs
EURACTIV News
- What ‘deal’ the EU can offer Trump
- COP29 outcome: EU upbeat on finance, disappointed on climate action
- Hard right’s Simion in with a chance as Romanians vote for president
- Developing nations blast $300 billion COP29 climate deal as insufficient
- Warsaw Mayor runs for Polish president as ruling party’s candidate